Literature DB >> 16251805

Integrated hepatitis C virus treatment: addressing comorbid substance use disorders and HIV infection.

Marilyn S Huckans1, Aaron D Blackwell, Todd A Harms, David W Indest, Peter Hauser.   

Abstract

OBJECTIVES: To examine hepatitis C virus (HCV) and HIV testing patterns within the Northwest Veterans Integrated Service Network (VISN 20).
METHODS: Using a comprehensive VISN 20 database, we retrospectively reviewed medical records of 293,445 veterans.
RESULTS: 32.8% of patients were tested for HCV, 5.5% were tested for HIV, and 4.3% were co-tested. Of those tested, 12.3% were HCV positive, 5.4% were HIV positive, and 1.6% were co-infected. 79.1% of HIV-positive patients were tested for HCV, 29.2% of whom tested positive. 34.8% of HCV-positive patients were tested for HIV, 4.9% of whom tested positive. Of those tested, HCV-positive patients were significantly more likely than HCV-negative patients to test positive for HIV; HIV-positive patients were no more likely to test positive for HCV than HIV-negative patients. HIV-positive patients with substance use disorders (SUD) were significantly more likely to test HCV positive than those without. Within the total sample, veterans with SUD were significantly more likely to be tested for both diseases and to test positive for HCV but not HIV. After controlling for other categories of SUD, veterans with a history of cocaine abuse compared with those without were at an increased risk of HIV infection and co-infection.
CONCLUSION: 79.1% of HIV-positive but only 34.8% of HCV-positive veterans were co-tested, suggesting barriers to HIV testing may exist in VISN 20. Results also indicate that HCV-positive patients are at increased risk for HIV infection and that HIV-positive patients with SUD are at increased risk of HCV infection; routine co-testing for these patients is therefore warranted. Given significant co-infection rates, HCV and HIV screening and testing should be increasingly integrated. Increased infection rates among patients with SUD also warrant integration of HCV and HIV screening and testing into mental health and addiction programmes.

Entities:  

Mesh:

Year:  2005        PMID: 16251805     DOI: 10.1097/01.aids.0000192078.49185.b0

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  15 in total

1.  Prospective memory in substance abusers at treatment entry: associations with education, neuropsychological functioning, and everyday memory lapses.

Authors:  Michael Weinborn; Steven Paul Woods; Stephanie O'Toole; Emily J Kellogg; Jonson Moyle
Journal:  Arch Clin Neuropsychol       Date:  2011-09-08       Impact factor: 2.813

2.  Risk for prescription opioid misuse among patients with a history of substance use disorder.

Authors:  Benjamin J Morasco; Dennis C Turk; Dennis M Donovan; Steven K Dobscha
Journal:  Drug Alcohol Depend       Date:  2012-07-18       Impact factor: 4.492

3.  Pain and opioid use in chronic liver disease: optimal treatment must address the mental health care needs of the patient.

Authors:  Jennifer M Loftis; Peter Hauser
Journal:  Dig Dis Sci       Date:  2013-10       Impact factor: 3.199

4.  Discounting of delayed rewards and executive dysfunction in individuals infected with hepatitis C.

Authors:  Marilyn Huckans; Adriana Seelye; Jonathan Woodhouse; Tiffany Parcel; Lisa Mull; Daniel Schwartz; Alex Mitchell; David Lahna; Amy Johnson; Jennifer Loftis; Steven Paul Woods; Suzanne H Mitchell; William Hoffman
Journal:  J Clin Exp Neuropsychol       Date:  2010-08-06       Impact factor: 2.475

5.  Development and Preliminary Evaluation of an Integrated Cognitive-Behavior Treatment for Chronic Pain and Substance Use Disorder in Patients with the Hepatitis C Virus.

Authors:  Benjamin J Morasco; David W Greaves; Travis I Lovejoy; Dennis C Turk; Steven K Dobscha; Peter Hauser
Journal:  Pain Med       Date:  2016-06-27       Impact factor: 3.750

6.  Awareness of hepatitis C infection among women with and at risk for HIV.

Authors:  Mardge H Cohen; Dennis Grey; Judith A Cook; Kathryn Anastos; Eric Seaberg; Michael Augenbraun; Pam Burian; Marion Peters; Mary Young; Audrey French
Journal:  J Gen Intern Med       Date:  2007-10-09       Impact factor: 5.128

7.  A comparison of risk factors for HCV-mono-infection, HIV-mono-infection, and HCV/HIV-co-infection in a community setting.

Authors:  Srigayatri Bollepalli; Kathleen Mathieson; Beata Jasiurkowski; Amy Hillier; John Post; Shakil Bhanu; Dean Martin; David H Van Thiel; Abdul Nadir
Journal:  Dig Dis Sci       Date:  2007-06-12       Impact factor: 3.199

8.  Antagonism between two intestinal parasites in humans: the importance of co-infection for infection risk and recovery dynamics.

Authors:  Aaron D Blackwell; Melanie Martin; Hillard Kaplan; Michael Gurven
Journal:  Proc Biol Sci       Date:  2013-08-28       Impact factor: 5.349

9.  The cognitive effects of hepatitis C in the presence and absence of a history of substance use disorder.

Authors:  Marilyn Huckans; Adriana Seelye; Tiffany Parcel; Lisa Mull; Jonathan Woodhouse; Danell Bjornson; Bret E Fuller; Jennifer M Loftis; Benjamin J Morasco; Anna W Sasaki; Daniel Storzbach; Peter Hauser
Journal:  J Int Neuropsychol Soc       Date:  2009-01       Impact factor: 2.892

Review 10.  A meta-analysis of the hepatitis C virus distribution in diverse racial/ethnic drug injector groups.

Authors:  Corina Lelutiu-Weinberger; Enrique R Pouget; Don D C Des Jarlais; Hannah L Cooper; Roberta Scheinmann; Rebecca Stern; Shiela M Strauss; Holly Hagan
Journal:  Soc Sci Med       Date:  2008-12-04       Impact factor: 4.634

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.